Table 3 Therapeutic sequence for the 113 patients treated with TPF induction chemotherapy for locally advanced head and neck cancer
Induction chemotherapy with TPF* regimen | |
Number of cycles – no. (%) | |
4 | 6 (5) |
3 | 78 (69) |
2 | 19 (17) |
1 | 10 (9) |
Fractionated cisplatin to C1 | |
Yes | 14 (12) |
No | 99 (88) |
Patients who received full induction chemotherapy – no. (%) | 70 (62) |
Induction chemotherapy protocol modifications – no. (%) | |
Interruption | 18 (16) |
Report | 7 (7) |
Dose reduction | 30 (31) |
Radiotherapy | |
Delay between the end of induction and the start of radiotherapy – median [min-max] | 36 days [24–107] |
Overall treatment time – median [min-max] | 49 days [27–72] |
Technique – no. (%) | |
IMRT* | 91 (87) |
Conformational | 13 (13) |
Interruption – no. (%) | 1 (1) |
Concomitant radiochemotherapy (excluding laryngeal preservation and post-operative irradiation) | |
Concomitant chemotherapy – no. (%) | 49 (43) |
Carboplatin AUC 1.5/week for 7 weeks | 25 (51) |
Cisplatin 40 mg/m2/week for 7 weeks or cisplatin 100 mg/m2 S1, S4, S7 | 18 (37) |
Cetuximab 400 mg/m2 at D-8 and 250 mg/m2/week for 7 weeks | 6 (12) |
Interruptions in concomitant chemotherapy – no. (%) | 26 (53) |
Carboplatin | 12 46) |
Cisplatin | 10 (39) |
Cetuximab | 4 (15) |
Patients who received the full course of treatment – no. (%) | 39 (35%) |